Millennium Management’s Amicus Therapeutics FOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $114M | Buy |
7,908,459
+4,913,370
| +164% | +$70.4M | 0.05% | 388 |
|
|
2025
Q4 | $42.7M | Sell |
2,995,089
-8,814,707
| -75% | -$86.6M | 0.02% | 913 |
|
|
2025
Q3 | $93.1M | Buy |
11,809,796
+4,388,156
| +59% | +$31.2M | 0.04% | 481 |
|
|
2025
Q2 | $42.5M | Buy |
7,421,640
+4,062,251
| +121% | +$26.2M | 0.02% | 919 |
|
|
2025
Q1 | $27.4M | Buy |
3,359,389
+2,902,375
| +635% | +$26.9M | 0.01% | 1226 |
|
|
2024
Q4 | $4.31M | Buy |
457,014
+44,449
| +11% | +$462K | ﹤0.01% | 2954 |
|
|
2024
Q3 | $4.41M | Sell |
412,565
-1,481,611
| -78% | -$16.1M | ﹤0.01% | 2950 |
|
|
2024
Q2 | $18.8M | Buy |
1,894,176
+1,792,277
| +1,759% | +$18.4M | 0.01% | 1554 |
|
|
2024
Q1 | $1.2M | Buy |
+101,899
| New | +$1.3M | ﹤0.01% | 4145 |
|
|
2023
Q3 | – | Sell |
-74,680
| Closed | -$938K | – | 6260 |
|
|
2023
Q2 | $938K | Sell |
74,680
-1,863,903
| -96% | -$22.1M | ﹤0.01% | 4095 |
|
|
2023
Q1 | $21.5M | Buy |
1,938,583
+1,467,981
| +312% | +$18.1M | 0.01% | 1282 |
|
|
2022
Q4 | $5.75M | Buy |
470,602
+420,898
| +847% | +$4.74M | ﹤0.01% | 2689 |
|
|
2022
Q3 | $519K | Sell |
49,704
-215,509
| -81% | -$2.4M | ﹤0.01% | 4946 |
|
|
2022
Q2 | $2.85M | Buy |
265,213
+171,980
| +184% | +$1.42M | ﹤0.01% | 3357 |
|
|
2022
Q1 | $883K | Buy |
93,233
+20,440
| +28% | +$192K | ﹤0.01% | 4653 |
|
|
2021
Q4 | $841K | Sell |
72,793
-164,166
| -69% | -$1.83M | ﹤0.01% | 4563 |
|
|
2021
Q3 | $2.26M | Buy |
236,959
+190,124
| +406% | +$1.94M | ﹤0.01% | 3765 |
|
|
2021
Q2 | $451K | Buy |
+46,835
| New | +$457K | ﹤0.01% | 5392 |
|
|
2021
Q1 | – | Sell |
-55,567
| Closed | -$1.28M | – | 6105 |
|
|
2020
Q4 | $1.28M | Sell |
55,567
-167,327
| -75% | -$3.42M | ﹤0.01% | 3567 |
|
|
2020
Q3 | $3.15K | Sell |
222,894
-630,429
| -74% | -$9.19M | ﹤0.01% | 2233 |
|
|
2020
Q2 | $12.9M | Sell |
853,323
-404,851
| -32% | -$4.93M | 0.02% | 1042 |
|
|
2020
Q1 | $11.6M | Sell |
1,258,174
-556,387
| -31% | -$5.29M | 0.03% | 756 |
|
|
2019
Q4 | $17.7M | Buy |
1,814,561
+485,220
| +37% | +$4.44M | 0.02% | 935 |
|
|
2019
Q3 | $10.7M | Buy |
1,329,341
+242,659
| +22% | +$2.63M | 0.02% | 1236 |
|
|
2019
Q2 | $13.6M | Sell |
1,086,682
-1,238,868
| -53% | -$15.7M | 0.02% | 1039 |
|
|
2019
Q1 | $31.6M | Buy |
2,325,550
+2,004,615
| +625% | +$24.5M | 0.05% | 542 |
|
|
2018
Q4 | $3.08M | Buy |
+320,935
| New | +$3.53M | ﹤0.01% | 1927 |
|
|
2018
Q2 | – | Sell |
-663,272
| Closed | -$9.98M | – | 3905 |
|
|
2018
Q1 | $9.98M | Sell |
663,272
-655,301
| -50% | -$9.97M | 0.01% | 1323 |
|
|
2017
Q4 | $19M | Buy |
+1,318,573
| New | +$18.1M | 0.03% | 932 |
|
|
2017
Q3 | – | Sell |
-362,790
| Closed | -$3.65M | – | 3615 |
|
|
2017
Q2 | $3.65M | Buy |
+362,790
| New | +$2.92M | 0.01% | 1713 |
|
|
2017
Q1 | – | Sell |
-126,091
| Closed | -$627K | – | 3592 |
|
|
2016
Q4 | $627K | Buy |
+126,091
| New | +$873K | ﹤0.01% | 2548 |
|
|
2016
Q3 | – | Sell |
-134,247
| Closed | -$733K | – | 3366 |
|
|
2016
Q2 | $733K | Buy |
+134,247
| New | +$939K | ﹤0.01% | 2307 |
|
|
2016
Q1 | – | Sell |
-37,531
| Closed | -$364K | – | 3391 |
|
|
2015
Q4 | $364K | Sell |
37,531
-3,696,975
| -99% | -$33.3M | ﹤0.01% | 2815 |
|
|
2015
Q3 | $52.2M | Sell |
3,734,506
-1,285,196
| -26% | -$20.2M | 0.1% | 230 |
|
|
2015
Q2 | $71M | Buy |
5,019,702
+702,767
| +16% | +$8.45M | 0.13% | 169 |
|
|
2015
Q1 | $47M | Buy |
4,316,935
+730,025
| +20% | +$6.44M | 0.09% | 295 |
|
|
2014
Q4 | $29.8M | Buy |
3,586,910
+2,105,876
| +142% | +$14.5M | 0.06% | 421 |
|
|
2014
Q3 | $8.81M | Buy |
1,481,034
+1,167,075
| +372% | +$6.11M | 0.02% | 934 |
|
|
2014
Q2 | $1.05M | Buy |
+313,959
| New | +$737K | ﹤0.01% | 2176 |
|
Other funds holding FOLD
VCM
PCM
VPM
GCL
Millennium Management's FOLD Position: Q1 2026 in Review
Millennium Management increased its Amicus Therapeutics (FOLD) stake by 164% in Q1 2026, buying an estimated $70.4M and bringing the position to 7,908,459 shares worth $114M. The position accounts for 0.05% of the portfolio, ranked #388.
Millennium Management first reported a position in FOLD in Q2 2014 and has held it in 39 quarters since. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.
- Millennium Management held 7,908,459 shares of Amicus Therapeutics worth $114M as of Q1 2026.
- Millennium Management bought 4,913,370 Amicus Therapeutics shares in Q1 2026, an estimated $70.4M.
- Amicus Therapeutics made up 0.05% of Millennium Management's portfolio in Q1 2026, its #388 holding.
- Millennium Management first reported a position in Amicus Therapeutics in Q2 2014 and has held it in 39 quarters since.
- 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.
Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.